The 2nd Meeting of National Control Laboratories for Vaccines and Biologicals in the Western Pacific

The Second Meeting of the National Control Laboratories for Vaccines and Biologicals in the Western Pacific, was jointly organized by the National Institute of Food and Drug Safety Evaluation of the Ministry of Food and Drug Safety in the Republic of Korea, and by the World Health Organization Regional Office for the Western Pacific. In the National Lot Release Systems session countries including Canada, China, Japan, Malaysia, Vietnam, and the Republic of Korea, all shared information on their current Lot Release Systems, including current practices and developments in risk-based official lot release of vaccines. In the session on Quality Control of Blood Products, experts from the National Institute for Biological Standards and Control shared quality control and research results for; blood coagulation factor VIII products, and the measurement of procoagulant activity in immunoglobulin products. Representatives from Japan proposed a regional collaborative study to test aggregated immunoglobulin free from complement activity. A cell-based Japanese encephalitis vaccine potency assay was proposed by representatives from Korea and they also called for voluntary participation of other National Control Laboratories in a collaborative study, on the first Korean Gloydius anti-venom standard. Participants agreed in general to continue communicating, and coordinate presentation of the study results.

[1]  M. Potapnev,et al.  Human normal immunoglobulin for intravenous administration: indications, effectiveness and safety of clinical application. , 2018, Immunopathology, Allergology, Infectology.

[2]  I. Hamaguchi,et al.  Establishment of a reference material for standardization of the anti-complementary activity test in intravenous immunoglobulin products used in Japan: A collaborative study. , 2017, Biologicals (Print).

[3]  K. Jung,et al.  The First Meeting of the National Control Laboratories for Vaccines and Biologicals in the Western Pacific in 2016 , 2017, Osong Public Health and Research Perspectives.

[4]  Cheol‐Hee Kim,et al.  A collaborative study of an alternative in vitro potency assay for the Japanese encephalitis vaccine. , 2016, Virus research.

[5]  T. Burnouf,et al.  Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products. , 2014, Biologicals : journal of the International Association of Biological Standardization.

[6]  M. Kaku,et al.  Immunogenicity of single-dose Vero cell-derived Japanese encephalitis vaccine in Japanese adults. , 2014, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[7]  R. Seitz,et al.  Modified Thrombin Generation Assay: Application To The Analysis Of Immunoglobulin Concentrates , 2010 .

[8]  A. Farrugia,et al.  Measurement of anticomplementary activity in therapeutic intravenous immunoglobulin preparations. , 1997, Biologicals : journal of the International Association of Biological Standardization.

[9]  R. Isbrucker,et al.  Health Canada's human vaccine lot release program: impact on the 3Rs , 2011 .